老年人多重用药安全管理专家共识

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (10): 627-640.

• 标准与共识 • 上一篇

老年人多重用药安全管理专家共识

中国老年医学研究会内分泌代谢分会, 中国毒理学会临床毒理专业委员会

收稿日期:2018-08-23 修回日期:2018-11-27 出版日期:2018-10-20 发布日期:2018-11-27
通讯作者: 李光伟,男,主任医师,内分泌与心血管研究。E-mail:guangweili45@126.com

Expert Consensus on Risk Management of Polypharmacy in Elderly

Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology

Received:2018-08-23 Revised:2018-11-27 Online:2018-10-20 Published:2018-11-27

摘要/Abstract

摘要： 我国是世界上老年人口最多的国家,多病共存的老年人多重用药情况不可避免且非常普遍。因此,越来越多医学和药学专家呼吁广大医务人员关注老年人多重用药的风险,并提出管理措施,以求避免或减少多药联合治疗时药物相互作用带来的损害。为了满足临床实践需求,进一步提高老年人群用药安全的水平,我国部分临床医学和药学专家经多次研讨,制定了本《老年人多重用药安全管理专家共识》以供临床参考,确保用药安全。

关键词: 老年人, 多重用药, 安全管理, 专家共识

Abstract: China has the largest elderly population in the world. Polypharmacy in the elderly with multiple diseases is inevitable and very common. In recent years, more and more medical and pharmaceutical experts appeal to pay attention to the risk of polypharmacy in elderly, and put forward management to avoid damage caused by drug interaction in multi-drug combination therapy. To meet the needs of clinical practice and further to improve the level of drug safety in elderly, a group of clinical medicine and pharmaceutical experts in China have worked out the "Expert Consensus on the Risk Management of Polypharmacy in Elderly" for clinical reference to ensure the safety of drug use.

Key words: elderly, polypharmacy, risk management, expert consensus

中图分类号:

R969.3

中国老年医学研究会内分泌代谢分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国药物警戒, 2018, 15(10): 627-640.

Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology. Expert Consensus on Risk Management of Polypharmacy in Elderly[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 627-640.

参考文献

[1] 殷立新,张立辉 . 特殊人群用药指导丛书:老年人用药指导[M]. 北京:人民卫生出版社,2012.
[2] 陶立群. 我国老年慢性病现状及发展趋势[J].老龄问题研究,2006(3):17-29.
[3] Ji L,Hu D,Pan C,et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J]. Am J Med,2013,126(10):925,e11-22.DOI:10.1016/j.amjmed.2013.02.035.
[4] Kaufmand W,Kelly J P,Rosenberg L,et al.Recent patterns of medication use in the ambulatory adult population of the United States:the slone survey[J]. JAMA,2002,287(3):337-344.
[5] Fialovd D,Topinkova E,Gambassi G,et al.Potentially inappropriate medication use among elderly home care patients in Europe[J]. JAMA,2005,293(11):1348-1358.DOI:10.1001/jama.293.11.1348.
[6] Kim H A,Shin J Y,Kim M H,et al.Prevalence and predictors of polypharmacy among Korean elderly[J].PLoS One,2014,9(6):e98043.DOI:10.1371/journal.pone.0098043.
[7] Lamd P,Mak C F,Chan S M,et al.Polypharmacy and inappropriate prescribing in elderly Hong Kong Chinese patients[J]. J Am Geriatr Soc,2010,58(1):203-205.DOI:10.1111/j.1532-5415. 2009. 02656.x.
[8] Johnell K,Klarin L.The relationship between number of drugs and potential drug-drug interactions in the elderly:a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register[J].Drug Saf,2007,30(10):911-918.
[9] 刘治军,韩红蕾. 药物相互作用基础与临床[J]. 3 版,北京:人民卫生出版社,2018.
[10] 张波,闫雪莲,王秋梅,等. 重视老年人多重用药问题[J]. 中华老年医学杂,2012,31(2):171-174.DOI:10.3760/cma.j.issn.0254-9026.2012.02.024.
[11] Kaku K .Efficacy of voglibose in type 2 diabetes[J]. Expert Opin Pharmacother,2014,15(8):1181-1190.DOI:10.1517/14656566.2014.918956.
[12] Balfour J A,Mctavish D.Acarbose.An update of its pharmacology and therapeutic use in diabetes mellitus[J]. Drugs,1993,46(6):1025-1054.
[13] Ahr H J,Boberg M,Krause H P,et al.Pharmacokinetics of acarbose.Part Ⅰ:absorption,concentration in plasma,metabolism and excretion after single administration of [14C]acarbose to rats,dogs and man[J].Arzneimittel for schung,1989,39(10):1254-1260.
[14] Miura T,Ueno K,Tanaka K,et al.Impairment of absorption of digoxin by acarbose[J].J Clin Pharmacol,1998,38(7):654-657.
[15] Morreale A P,Janerzky K.Probable interaction of warfarin and acarbose[J].Am J Health Syst Pharm,1997,54(13):1551-1552.
[16] Dash R P,Babu R J,Srinivas N R.Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose,voglibose and miglitol in the treatment of type 2 diabetes mellitus[J].Xenobiotica,2018,48(1):89-108. DOI:10.1080/00498254.2016.1275063.
[17] Scheen A J.Dipeptidylpeptidase-4 inhibitors (gliptins):focus on drug-drug interactions[J].Clin Pharmacokinet,2010,49(9):573-588. DOI:10.2165/11532980-000000000-00000.
[18] 陈莉明 .二肽基肽酶Ⅳ抑制剂类口服降糖药的药化性质和药理活性综合比较分析[J]. 中华糖尿病杂志,2016,8(8):508-510.
DOI:10.OI:10.3760/cma.j.issn.1674-5809.2016.08.014.
[19] Graefe-mody U,Retlich S,Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin[J].Clin Pharmacokinet,2012,51(7):411-427. DOI:10.2165/11630900-000000000-00000.
[20] Brown N J,Byiers S,Carr D,et al.Dipeptidyl peptidase- Ⅳ inhibitor use associated with increased risk of ACE inhibitor-associated angioedema[J].Hypertension,2009,54(3):516-523. DOI:10.1161/HYPERTENSIONAHA.109.134197.

老年人多重用药安全管理专家共识

Expert Consensus on Risk Management of Polypharmacy in Elderly

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	朱愿超, 张亚同, 胡欣. 老年人用药风险管理原则和措施[J]. 中国药物警戒, 2023, 20(9): 1031-1034.
[2]	袁偲偲, 王广燕, 李轶凡, 李瑞莲, 杜博冉, 冯欣. 基于失效模式与效应分析的麻精药品临床管理安全相关风险因素研究[J]. 中国药物警戒, 2023, 20(9): 1027-1030.
[3]	朱愿超, 赵明, 胡欣, 施红. 药师主导老年多重用药患者管理的思考和实践[J]. 中国药物警戒, 2023, 20(7): 817-821.
[4]	赵暄, 郭婧, 陈宁, 梅隆, 郑婷婷, 张丽芳, 张威. 医疗用毒性药品在医疗机构中的安全管理探讨[J]. 中国药物警戒, 2023, 20(6): 705-708.
[5]	刘红亮, 王青, 侯永芳. 基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施[J]. 中国药物警戒, 2023, 20(10): 1095-1098.
[6]	马冰冰, 张晓朦, 张冰, 林志健, 吕锦涛. 基于文献分析的老年人中成药合理用药与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 595-599.
[7]	柴晓利, 张臣, 丰庆春, 刘欢. 非瓣膜性心房颤动老年患者用药现状及影响因素分析[J]. 中国药物警戒, 2022, 19(3): 302-305.
[8]	董敏, 邹彤, 徐蕾, 何清华, 裴作为, 汪芳. 多重用药对老年冠心病合并心房颤动患者远期预后的影响[J]. 中国药物警戒, 2021, 18(2): 126-132.
[9]	张捷, 毛乾泰, 艾超. 门诊老年患者潜在不适当用药评价[J]. 中国药物警戒, 2021, 18(11): 1087-1090.
[10]	庄红艳，刘珊珊，果伟，马辛, 郝红兵，张怡，牛松. 121例老年精神科药品不良反应报告分析[J]. 中国药物警戒, 2017, 14(2): 105-108.
[11]	范燕, 夏东胜. 我国药品说明书老年人用药标示的问题与对策[J]. 中国药物警戒, 2016, 13(6): 341-343.
[12]	施秀华, 江长缨. 上海某社区老年人用药依从性及影响因素分析[J]. 中国药物警戒, 2015, 12(7): 434-438.
[13]	沈芊,刘琛,王育琴 . 400例老年人严重药品不良反应病例分析[J]. 中国药物警戒, 2013, 10(4): 228-231.
[14]	赵燕, 崔歆, 杨兴华, 张洪波. 某院老年肺部感染患者抗感染药应用现况调查[J]. 中国药物警戒, 2011, 8(2): 71-74.
[15]	金丹, 杨乐, 杨月明, 王瑜歆, 魏晶, 王嘉仡, 杜晓曦. 2006年全国老年人严重药品不良反应报告分析[J]. 中国药物警戒, 2010, 7(2): 112-115.